The accepted approach for Corporate Innovation leaders is to secure buy-in from all stakeholders, in order to secure success. This article (first in a series) argues against this approach, aiming for a more tempered effort, that seeks enough buy-in to push forward.
I recently re-read the 2012 HBR article titled “Get the Corporate Antibodies on Your Side” by Mitra Best. The article’s underlying theme is that you need to run an inclusive approach to innovation activities, generating buy-in and support from all of your stakeholders (or potential antibodies), in order to drive the success of your efforts.
